523 related articles for article (PubMed ID: 21135147)
1. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.
Prins RM; Soto H; Konkankit V; Odesa SK; Eskin A; Yong WH; Nelson SF; Liau LM
Clin Cancer Res; 2011 Mar; 17(6):1603-15. PubMed ID: 21135147
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
Liau LM; Prins RM; Kiertscher SM; Odesa SK; Kremen TJ; Giovannone AJ; Lin JW; Chute DJ; Mischel PS; Cloughesy TF; Roth MD
Clin Cancer Res; 2005 Aug; 11(15):5515-25. PubMed ID: 16061868
[TBL] [Abstract][Full Text] [Related]
5. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
7. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
8. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
Ardon H; Van Gool SW; Verschuere T; Maes W; Fieuws S; Sciot R; Wilms G; Demaerel P; Goffin J; Van Calenbergh F; Menten J; Clement P; Debiec-Rychter M; De Vleeschouwer S
Cancer Immunol Immunother; 2012 Nov; 61(11):2033-44. PubMed ID: 22527250
[TBL] [Abstract][Full Text] [Related]
9. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.
Rodríguez-Ruiz ME; Perez-Gracia JL; Rodríguez I; Alfaro C; Oñate C; Pérez G; Gil-Bazo I; Benito A; Inogés S; López-Diaz de Cerio A; Ponz-Sarvise M; Resano L; Berraondo P; Barbés B; Martin-Algarra S; Gúrpide A; Sanmamed MF; de Andrea C; Salazar AM; Melero I
Ann Oncol; 2018 May; 29(5):1312-1319. PubMed ID: 29554212
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
Rudnick JD; Sarmiento JM; Uy B; Nuno M; Wheeler CJ; Mazer MJ; Wang H; Hu JL; Chu RM; Phuphanich S; Black KL; Yu JS
J Clin Neurosci; 2020 Apr; 74():187-193. PubMed ID: 32169363
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
[TBL] [Abstract][Full Text] [Related]
13. Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients.
Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
Res Sq; 2023 Sep; ():. PubMed ID: 37790490
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients.
Wang QT; Nie Y; Sun SN; Lin T; Han RJ; Jiang J; Li Z; Li JQ; Xiao YP; Fan YY; Yuan XH; Zhang H; Zhao BB; Zeng M; Li SY; Liao HX; Zhang J; He YW
Cancer Immunol Immunother; 2020 Jul; 69(7):1375-1387. PubMed ID: 32078016
[TBL] [Abstract][Full Text] [Related]
15. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.
Yamanaka R; Abe T; Yajima N; Tsuchiya N; Homma J; Kobayashi T; Narita M; Takahashi M; Tanaka R
Br J Cancer; 2003 Oct; 89(7):1172-9. PubMed ID: 14520441
[TBL] [Abstract][Full Text] [Related]
17. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.
Ardon H; Van Gool S; Lopes IS; Maes W; Sciot R; Wilms G; Demaerel P; Bijttebier P; Claes L; Goffin J; Van Calenbergh F; De Vleeschouwer S
J Neurooncol; 2010 Sep; 99(2):261-72. PubMed ID: 20146084
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.
Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB; Paulos CM; Salazar AM; Nishimura MI; Rubinstein MP; Li Z; Cole DJ
J Hematol Oncol; 2017 Apr; 10(1):82. PubMed ID: 28388966
[TBL] [Abstract][Full Text] [Related]
19. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.
Lasky JL; Panosyan EH; Plant A; Davidson T; Yong WH; Prins RM; Liau LM; Moore TB
Anticancer Res; 2013 May; 33(5):2047-56. PubMed ID: 23645755
[TBL] [Abstract][Full Text] [Related]
20. Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
Aerts JGJV; de Goeje PL; Cornelissen R; Kaijen-Lambers MEH; Bezemer K; van der Leest CH; Mahaweni NM; Kunert A; Eskens FALM; Waasdorp C; Braakman E; van der Holt B; Vulto AG; Hendriks RW; Hegmans JPJJ; Hoogsteden HC
Clin Cancer Res; 2018 Feb; 24(4):766-776. PubMed ID: 29233904
[No Abstract] [Full Text] [Related]
[Next] [New Search]